[go: up one dir, main page]

IT1400609B1 - Associazione di inibitori della xantina ossidasi e metformina e loro uso. - Google Patents

Associazione di inibitori della xantina ossidasi e metformina e loro uso.

Info

Publication number
IT1400609B1
IT1400609B1 ITRM2010A000233A ITRM20100233A IT1400609B1 IT 1400609 B1 IT1400609 B1 IT 1400609B1 IT RM2010A000233 A ITRM2010A000233 A IT RM2010A000233A IT RM20100233 A ITRM20100233 A IT RM20100233A IT 1400609 B1 IT1400609 B1 IT 1400609B1
Authority
IT
Italy
Prior art keywords
xanthin
metformin
association
oxidase
inhibitors
Prior art date
Application number
ITRM2010A000233A
Other languages
English (en)
Inventor
Carlo Alberto Maggi
Sandro Giuliani
Francesco Melani
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Priority to ITRM2010A000233A priority Critical patent/IT1400609B1/it
Priority to ARP110101591A priority patent/AR081024A1/es
Priority to TW100116121A priority patent/TW201206431A/zh
Priority to PCT/EP2011/057412 priority patent/WO2011141419A1/en
Publication of ITRM20100233A1 publication Critical patent/ITRM20100233A1/it
Priority to CR20120617A priority patent/CR20120617A/es
Application granted granted Critical
Publication of IT1400609B1 publication Critical patent/IT1400609B1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ITRM2010A000233A 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e metformina e loro uso. IT1400609B1 (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ITRM2010A000233A IT1400609B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e metformina e loro uso.
ARP110101591A AR081024A1 (es) 2010-05-10 2011-05-09 Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso
TW100116121A TW201206431A (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and metformin and use thereof
PCT/EP2011/057412 WO2011141419A1 (en) 2010-05-10 2011-05-09 Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
CR20120617A CR20120617A (es) 2010-05-10 2012-12-06 Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000233A IT1400609B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e metformina e loro uso.

Publications (2)

Publication Number Publication Date
ITRM20100233A1 ITRM20100233A1 (it) 2011-11-11
IT1400609B1 true IT1400609B1 (it) 2013-06-14

Family

ID=43519819

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2010A000233A IT1400609B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e metformina e loro uso.

Country Status (5)

Country Link
AR (1) AR081024A1 (it)
CR (1) CR20120617A (it)
IT (1) IT1400609B1 (it)
TW (1) TW201206431A (it)
WO (1) WO2011141419A1 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105743RA (en) * 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Methods for treating or preventing gout or hyperuricemia
CA3121913A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2024033705A1 (en) * 2022-08-08 2024-02-15 Xortx Therapeutics, Inc. Xanthine oxidase inhibitor formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE142494T1 (de) 1990-11-30 1996-09-15 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
PT1956015E (pt) 1998-06-19 2011-11-02 Teijin Pharma Ltd Polimorfo de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil- 5-tiazole-carboxílico e método para a sua produção
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
WO2007019153A2 (en) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
CA2669935A1 (en) 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
WO2008127893A1 (en) * 2007-04-04 2008-10-23 Hight H Thomas Niacin-based pharmaceutical compositions
US20100137289A1 (en) * 2007-04-17 2010-06-03 Johnson Richard J Methods and Compositions for Ameliorating Thiazide Induced Hyperlipidemia

Also Published As

Publication number Publication date
TW201206431A (en) 2012-02-16
CR20120617A (es) 2013-03-04
AR081024A1 (es) 2012-05-30
WO2011141419A1 (en) 2011-11-17
ITRM20100233A1 (it) 2011-11-11

Similar Documents

Publication Publication Date Title
IL264441A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
CY2020025I2 (el) Αναστολεις βητα-λακταμασων
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
DK2536722T3 (da) Bicycliske forbindelser og deres anvendelse som dual-c-src-/jak-inhibitorer
CY2019026I1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
SMT201600023B (it) Composti piridazinonici e loro uso come inibitori di daao
HUE046932T2 (hu) Argináz inhibitorok és felhasználási eljárások
BR112013025354A2 (pt) combinações de compostos de inibidor de akt e agentes quimioterápicos e métodos de uso
SMT201500271B (it) Inibitori di neprilisina
HK1199725A1 (zh) 雜環化合物及其用途
DK3178818T3 (da) Pyrazolylquinoxalinkinasehæmmere
HUE037937T2 (hu) Arilciklopropilamin-alapú LSD1-demetiláz inhibitorok és gyógyászati alkalmazásuk
CO6930362A2 (es) Compuesto heterocíclico y su uso
PL2504336T3 (pl) Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
EP2299999A4 (en) STAT3 INHIBITORS
DK2483271T3 (da) Pyrazolindionderivater som NADPH-oxidaseinhibitorer
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
BRPI1007494A2 (pt) composto e uso do mesmo
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
DK3597650T3 (da) Aldosereduktasehæmmere og anvendelser deraf
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
DK2513106T3 (da) Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer